Lenalidomide, Rituximab and Combination Chemotherapy Versus Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Highly Aggressive Non-Hodgkin B-cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04152577

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:37:31.350701+00:00

Published At

2019-11-05T00:00:00+00:00

Record Updated At

2019-11-05

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Lymphoma, B-Cell"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2019-11-05"

protocolSection.identificationModule.nctId

"NCT04152577"

protocolSection.identificationModule.officialTitle

"Lenalidomide, Rituximab and Combination Chemotherapy Versus Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Highly Aggressive Non-Hodgkin B-cell Lymphoma"

protocolSection.statusModule.overallStatus

"UNKNOWN"

protocolSection.designModule.phases

["PHASE4"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Lymphoma, B-Cell (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.